Last updated on June 2020

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies


Brief description of study

The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

Detailed Study Description

Combined treatment with MCS110 and PDR001 is expected to result in TAM depletion, enhanced T-cell activation and synergistic antitumor activity in the clinical setting.

Clinical Study Identifier: NCT02807844

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.